Skip to main content
60°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
30.70
-1.03 (-3.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Akero Therapeutics Inc
< Previous
1
2
3
4
Next >
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 12, 2024
Via
Benzinga
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
August 09, 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
July 15, 2024
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of...
Via
Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
June 05, 2024
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.
Via
Investor's Business Daily
Akero Therapeutics: Q4 Earnings Insights
February 29, 2024
Via
Benzinga
11 Analysts Have This to Say About Akero Therapeutics
November 14, 2023
Via
Benzinga
Akero Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
The Week Ahead: What's Next
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024
May 10, 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...
Via
Benzinga
Why Akero Therapeutics Shares Are Slumping This Week
October 12, 2023
Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.
Via
The Motley Fool
Analyst Ratings for Akero Therapeutics
October 11, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
March 04, 2024
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment.
Via
Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing.
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 04, 2024
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
February 23, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
October 13, 2023
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance...
Via
Benzinga
E2open, Sharecare And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
October 12, 2023
U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward
October 11, 2023
Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 11, 2023
Via
Benzinga
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
October 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 11, 2023
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in...
Via
Benzinga
Why Shares of 89bio Plummeted on Tuesday
October 10, 2023
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Via
The Motley Fool
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.